SHPMY SHANGHAI PHARMACEU
- 7.965
- -0.035-0.44%
SHANGHAI PHARMACEU News
Shanghai Industrial Investment (Holdings) Company Limited increases shareholding in SH PHARMA (02607) by 0.16 million shares at a price of about 12.47 HKD per share.
On January 7, Shanghai Industrial Investment (Holdings) Company Limited increased its shareholding in SH PHARMA (02607) by 0.16 million shares, at a price of 12.4705 HKD per share, with a total amount of approximately 1.9953 million HKD.
SH PHARMA (02607.HK) received Shareholding of 0.16 million shares Listed in Hong Kong from Shanghai Industrial Investment (Holdings) Company Limited, valued at approximately 1.9953 million Hong Kong dollars.
On January 9, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 9, Shanghai Industrial Investment (Holdings) Company Limited increased its shareholding by 160,000 shares of SH PHARMA (02607.HK) at an average price of HK$12.4705 per share on January 7, valued at approximately HK$1.9953 million. After the shareholding increase, Shanghai Industrial Investment (Holdings) Company.
BOCOM INTL raises the Target Price for Hutchmed (China) (00013.HK) to 44 yuan, an excellent price for selling equity in the joint venture company.
Hutchmed (China) (00013.HK) recently announced that it will invest 0.608 billion USD to sell 45% of its equity in Shanghai Hutchmed to Juniper Health and SH PHARMA (02607.HK). BOCOM INTL believes the terms of this Trade are reasonable, the price is excellent, and it will help the company further focus on its core business of innovative research and development. The funds raised are expected to be used for the development of internal product pipelines, promoting the strategic development of the core Business, including the next-generation antibody-drug conjugate (ATTC) platform, which is beneficial for long-term growth in the future. Therefore, BOCOM INTL has raised Hutchmed (China)'s Target Price to 44 yuan, maintaining a "Buy" rating.
Express News | China International Capital Corporation: Maintains SH PHARMA as "Outperform Industry" rating with a Target Price of 23.3 yuan.
Research Reports Gold Digger丨CICC: Maintain SH PHARMA "Outperform Industry" rating Target Price 23.3 yuan.
On January 7, Gelonghui reported that China International Capital Corporation's Research Reports pointed out that SH PHARMA (601607.SH) acquisition is expected to enrich the Traditional Chinese Medicine matrix, with new gastrointestinal products approved for launch. This acquisition is expected to enhance the company's profits and strengthen SH PHARMA's evidence-based medicine and academic promotion capabilities. It is believed that the successful experience of Shexiang Baoxin Wan will serve as a reference for the secondary development of the company’s coronary heart disease products such as Guanyinxing Pian, Silver Ketone Ester series, and Yangxin Mingshi Pian. Additionally, as of December 2024, SH PHARMA has nearly 2,300 professional academic promotion team members. Furthermore, New China Life Insurance is bullish on the company's long-term development.
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
SH PHARMA (601607): The acquisition is expected to enrich the Traditional Chinese Medicine matrix, and new digestive products have been approved for market launch.
Company Update On January 1, 2025, the company announced plans to jointly acquire the equity of Hutchmed (China) held by Shanghai Hutchmed Industry with designated entities of Shanghai Jinfuping Health Service. Among them, SH PHARMA intends to invest its own funds of 0.995 billion yuan.
HSBC Research's investment rating and Target Price for pharmaceutical stocks (table).
HSBC Research has released a report listing the investment ratings and Target Prices for Chinese pharmaceutical stocks as follows: Stocks | Investment Rating | Target Price (HKD) FOSUN PHARMA (02196.HK) | Hold | 13 HKD HANSOH PHARMA (03692.HK) | Buy | 22 HKD CHINA NATIONAL PHARMACEUTICAL (01177.HK) | Buy | 4.1 HKD CSPC PHARMA (01093.HK) | Hold | 5.2 HKD CMS (00867.HK) | Buy | 9.5 HKD LIVZON PHARMA (01513.HK) | Buy
HSBC Research: The visibility of the pharmaceutical and medical device sub-sectors in mainland China has increased. Preference for BEIGENE (BGNE.US), China National Pharmaceutical Group (01177.HK), and HYGEIA HEALTH (06078.HK), among others.
HSBC Research published a report indicating that the mainland pharmaceutical and healthcare Industry experienced a difficult year last year. With a low profit comparison base, a slowdown in policy impact, and improved visibility of growth recovery, the firm is more optimistic about the Industry's outlook this year, expecting that overseas expansion will be one of the pillars for the Industry this year. The rapidly changing policies and macro environment require pharmaceutical company management to adapt quickly, while tightened medical insurance is expected to encourage management to increase investments to boost revenue. The firm stated that the valuation of the mainland pharmaceutical and healthcare Industry is currently one standard deviation below the historical forward average. As profits are expected to bottom out and recover this year, the average earnings per share for the pharmaceutical and healthcare companies covered by the firm is expected to increase by 1.
GF SEC: Maintains the "Buy" rating for Hutchmed (China) with a fair value of HKD 41.35.
GF SEC released a research report stating that it maintains a "Buy" rating on Hutchmed (China) (00013), expecting the Net income for 2024-2026 to be 0.005, 0.02, and 0.074 billion USD respectively. Using the DCF method, the company's fair value is estimated at HKD 41.35 per share (1 USD = 7.78 HKD). The company's R&D, commercialization, and overseas capabilities have been preliminarily validated, and there is a sufficient pipeline of differentiated innovation. As various products gradually enter the harvest period. The main points from GF SEC are as follows: Event 1: The company announced on January 2, 2025, the joint therapy of Savolitinib and Osimertinib for the treatment of patients with.
Shanghai Pharmaceuticals Holding and Yunnan Baiyao Renew Sales Agreement for 2025
Express News | SH PHARMA: Isosorbide mononitrate injection has passed the consistency evaluation for generic drugs.
Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal
Hutchmed (China) (00013.HK) rose over 7% in early trading, selling its stake in Shanghai Hutchmed Pharmaceuticals for 4.5 billion yuan.
Hutchmed (China) (00013.HK) opened today (2nd) with a rise of 3.1%, and the increase expanded, reaching a high of 24.4 yuan. Currently, it is reported at 24.2 yuan, up 7.32%, with a trading volume of 5.3285 million shares, involving 0.127 billion yuan. Hutchmed (China) has signed agreements with SH PHARMA (02607.HK) and Jinfuhuan, selling 10% and 35% equity stakes in Shanghai Hutchmed Pharmaceutical, respectively, cashing out a total of 4.48 billion yuan. Hutchmed (China) stated that after the Trade is completed, it will further optimize the group's capital and debt structure, and allow the group to concentrate its resources on its core Business areas. In addition, Hutchmed (China) announced that Worui
SH PHARMA (02607.HK) spent about 0.995 billion RMB to purchase a 10% stake in Shanghai Henyang Pharmaceutical.
SH PHARMA (02607.HK) announced that on December 31 last year, it entered into a share transfer agreement with Hutchison Whampoa Investments. It is reported that SH PHARMA agreed to acquire a 10% stake in 'Shanghai Hutchison Pharma' from Hutchison Whampoa Investments for approximately 0.995 billion yuan. On the same day, SH PHARMA's independent third party, Jinpu Health, entered into a share transfer agreement with Hutchison Whampoa Investments. It is reported that Jinpu Health or its designated entity will acquire a 35% stake in 'Shanghai Hutchison Pharma' from Hutchison Whampoa Investments. As of yesterday (the 1st), 'Shanghai Hutchison Pharma' is held by Hutchison Whampoa Investments and SH PHARMA's wholly-owned subsidiary, Shangyao Medicinal Materials, which each hold 50% of the equity. Upon completion of the acquisition.
Express News | Hutchmed (China): Plans to sell 45% of its subsidiary for approximately 0.608 billion USD.
Express News | SH PHARMA has terminated three clinical trial projects in the USA, with a cumulative R&D investment exceeding 80 million yuan.
HUTCHMED to Divest 45% Stake in JV With Shanghai Pharma
Express News | SH PHARMA: Decided to terminate the clinical trials and subsequent development of three research projects.
SH PHARMA (601607.SH): Termination of projects I001-B (USA), I022 (USA), C012 (USA).
On January 1, Gelonghui reported that SH PHARMA (601607.SH) announced the decision to terminate the clinical trials and subsequent development of three research and development projects: I001-B (USA), I022 (USA), and C012 (USA). This decision was made after a comprehensive assessment of factors such as the future market value of the R&D projects, business synergy, and subsequent development investment. Among them, I001-B (USA) and I022 (USA) are in Phase II clinical trials in the USA, while C012 (USA) has received approval from the USA Food and Drug Administration (referred to as "FDA").
No Data